1. Verhelst G. Valeriana officinalis L. (Echte valeriaan). In: Groot handboek geneeskrachtige planten. Wevelgem, Belgium: Mannavita BVBA; 2006.
2. Shinjyo N, Waddell G, Green J. Valerian Root in Treating Sleep Problems and Associated Disorders—A Systematic Review and Meta-Analysis. J Evid Based Complementary Altern Med. 2020 Jan 1;25:2515690X2096732.
3. Khom S, Strommer B, Ramharter J, Schwarz T, Schwarzer C, Erker T, et al. Valerenic acid derivatives as novel subunit-selective GABAA receptor ligands - in vitro and in vivo characterization. Br J Pharmacol. 2010 Sep;161(1):65–78.
4. Sieghart W. Pharmacology of benzodiazepine receptors: an update. J Psychiatry Neurosci. 1994 Jan;19(1):24–9.
5. Mulyawan E, Ahmad MR, Islam AA, Massi MuhN, Hatta M, Arif SK. Analysis of GABRB3 Protein Level After Administration of Valerian Extract (Valeriana officinalis) in BALB/c mice. PJ. 2020 Jun 18;12(4):821–7.
6. Boonstra E, de Kleijn R, Colzato LS, Alkemade A, Forstmann BU, Nieuwenhuis S. Neurotransmitters as food supplements: the effects of GABA on brain and behavior. Front Psychol [Internet]. 2015 Oct 6 [cited 2021 Feb 4];6. Available from: http://journal.frontiersin.org/Article/10.3389/fpsyg.2015.01520/abstract
7. Ngo D-H, Vo TS. An Updated Review on Pharmaceutical Properties of Gamma-Aminobutyric Acid. Molecules. 2019 Jul 24;24(15):2678.
8. España RA, Scammell TE. Sleep neurobiology from a clinical perspective. Sleep. 2011 Jul 1;34(7):845–58.
9. Fox JH, Lowry CA. Corticotropin-releasing factor-related peptides, serotonergic systems, and emotional behavior. Front Neurosci. 2013 Sep 20;7:169.
10. Dietz BM, Mahady GB, Pauli GF, Farnsworth NR. Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro. Brain Res Mol Brain Res. 2005 Aug 18;138(2):191–7.
11. Sagi Y, Medrihan L, George K, Barney M, McCabe KA, Greengard P. Emergence of 5-HT5A signaling in parvalbumin neurons mediates delayed antidepressant action. Mol Psychiatry. 2020 Jun;25(6):1191–201.
12. Jung HY, Yoo DY, Kim W, Nam SM, Kim JW, Choi JH, et al. Valeriana officinalis root extract suppresses physical stress by electric shock and psychological stress by nociceptive stimulation-evoked responses by decreasing the ratio of monoamine neurotransmitters to their metabolites. BMC Complement Altern Med. 2014 Dec 11;14:476.
13. Jung HY, Yoo DY, Nam SM, Kim JW, Choi JH, Yoo M, et al. Valerenic Acid Protects Against Physical and Psychological Stress by Reducing the Turnover of Serotonin and Norepinephrine in Mouse Hippocampus-Amygdala Region. J Med Food. 2015 Dec;18(12):1333–9.
14. Calker D, Biber K, Domschke K, Serchov T. The role of adenosine receptors in mood and anxiety disorders. J Neurochem. 2019 Oct;151(1):11–27.
15. Bartoli F, Burnstock G, Crocamo C, Carrà G. Purinergic Signaling and Related Biomarkers in Depression. Brain Sci. 2020 Mar 12;10(3).
16. Lacher SK, Mayer R, Sichardt K, Nieber K, Müller CE. Interaction of valerian extracts of different polarity with adenosine receptors: Identification of isovaltrate as an inverse agonist at A1 receptors. Biochemical Pharmacology. 2007 Jan;73(2):248–58.
17. Maurmann N, Reolon GK, Rech SB, Fett-Neto AG, Roesler R. A Valepotriate Fraction of Valeriana glechomifolia Shows Sedative and Anxiolytic Properties and Impairs Recognition But Not Aversive Memory in Mice. Evidence-Based Complementary and Alternative Medicine. 2011;2011:1–7.
18. Müller LG, Salles LA, Stein AC, Betti AH, Sakamoto S, Cassel E, et al. Antidepressant-like effect of Valeriana glechomifolia Meyer (Valerianaceae) in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2012 Jan;36(1):101–9.
19. Torssell K, Wahlberg K, Alnås Å, Hemmingsson S, Kullberg L, Blinc R, et al. Isolation, Structure, and Synthesis of Alkaloids from Valeriana officinalis L.. Acta Chem Scand. 1967;21:53–62.
20. Hung S-Y, Fu W-M. Drug candidates in clinical trials for Alzheimer’s disease. J Biomed Sci. 2017 Jul 19;24(1):47.
21. Sam C, Bordoni B. Physiology, Acetylcholine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [cited 2021 Feb 24]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK557825/
22. Di Lorenzo C, Colombo F, Biella S, Stockley C, Restani P. Polyphenols and Human Health: The Role of Bioavailability. Nutrients. 2021 Jan 19;13(1).
23. Zhang Y-J, Gan R-Y, Li S, Zhou Y, Li A-N, Xu D-P, et al. Antioxidant Phytochemicals for the Prevention and Treatment of Chronic Diseases. Molecules. 2015 Nov 27;20(12):21138–56.
24. Rodríguez-Cruz A, Romo-Mancillas A, Mendiola-Precoma J, Escobar-Cabrera JE, García-Alcocer G, Berumen LC. “Effect of valerenic acid on neuroinflammation in a MPTP-induced mouse model of Parkinson’s disease.” IBRO Reports. 2020 Jun;8:28–35.
25. Pino A, Palumbo DR, Samperi S, De Pasquale R, Sturlese E, Circosta C, et al. Relaxing effects of <I>Valeriana officinalis</I> extracts on isolated human non-pregnant uterine muscle. j pharm pharmacol. 2009 Feb 1;61(2):251–6.
26. Gamma-aminobutyric (GABA). Professional Monograph. Natural Medicines; 2020.
27. Wheatley D. Kava and valerian in the treatment of stress-induced insomnia. Phytother Res. 2001 Sep;15(6):549–51.
28. Taavoni S, Ekbatani N, Kashaniyan M, Haghani H. Effect of valerian on sleep quality in postmenopausal women: a randomized placebo-controlled clinical trial. Menopause. 2011 Sep;18(9):951–5.
29. Barton DL, Atherton PJ, Bauer BA, Moore DF, Mattar BI, Lavasseur BI, et al. The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5). J Support Oncol. 2011 Feb;9(1):24–31.
30. Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry. 2000 Mar;33(2):47–53.
31. Andreatini R, Sartori VA, Seabra MLV, Leite JR. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res. 2002 Nov;16(7):650–4.
32. Ahmadi M, Khalili H, Abbasian L, Ghaeli P. Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial. Ann Pharmacother. 2017 Jun;51(6):457–64.
33. Groen RN, Ryan O, Wigman JTW, Riese H, Penninx BWJH, Giltay EJ, et al. Comorbidity between depression and anxiety: assessing the role of bridge mental states in dynamic psychological networks. BMC Med. 2020 Sep 29;18(1):308.
34. Müller D, Pfeil T, von den Driesch V. Treating depression comorbid with anxiety – results of an open, practice-oriented study with St John’s wort WS® 5572 and valerian extract in high doses. Phytomedicine. 2003 Jan;10:25–30.
35. Trompetter I, Krick B, Weiss G. Herbal triplet in treatment of nervous agitation in children. Wien Med Wochenschr. 2013 Feb;163(3–4):52–7.
36. Cropley M, Cave Z, Ellis J, Middleton RW. Effect of Kava and Valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. Phytother Res. 2002 Feb;16(1):23–7.
37. Jenabi E, Shobeiri F, Hazavehei SMM, Roshanaei G. The effect of Valerian on the severity and frequency of hot flashes: A triple-blind randomized clinical trial. Women & Health. 2018 Mar 16;58(3):297–304.
38. Mirabi P, Mojab F. The effects of valerian root on hot flashes in menopausal women. Iran J Pharm Res. 2013;12(1):217–22.
39. Mirabi P, Dolatian M, Mojab F, Majd HA. Effects of valerian on the severity and systemic manifestations of dysmenorrhea. International Journal of Gynecology & Obstetrics. 2011 Dec;115(3):285–8.
40. Behboodi Moghadam Z, Rezaei E, Shirood Gholami R, Kheirkhah M, Haghani H. The effect of Valerian root extract on the severity of pre menstrual syndrome symptoms. J Tradit Complement Med. 2016 Jul;6(3):309–15.
41. Azizi H, Shojaii A, Hashem-Dabaghian F, Noras M, Boroumand A, Ebadolahzadeh Haghani B, et al. Effects of Valeriana officinalis (Valerian) on tension-type headache: A randomized, placebo-controlled, double-blind clinical trial. Avicenna J Phytomed. 2020 Jun;10(3):297–304.
42. Samaei A, Nobahar M, Hydarinia-Naieni Z, Ebrahimian AA, Tammadon MR, Ghorbani R, et al. Effect of valerian on cognitive disorders and electroencephalography in hemodialysis patients: a randomized, cross over, double-blind clinical trial. BMC Nephrol. 2018 Dec;19(1):379.
43. Hong K-B, Park Y, Suh HJ. Sleep-promoting effects of the GABA/5-HTP mixture in vertebrate models. Behav Brain Res. 2016 Sep 1;310:36–41.
44. Candelario M, Cuellar E, Reyes-Ruiz JM, Darabedian N, Feimeng Z, Miledi R, et al. Direct evidence for GABAergic activity of Withania somnifera on mammalian ionotropic GABAA and GABA? receptors. Journal of Ethnopharmacology. 2015 Aug 2;171:264–72.
45. Kennedy DO, Little W, Haskell CF, Scholey AB. Anxiolytic effects of a combination ofMelissa ofcinalis andValeriana ofcinalis during laboratory induced stress. Phytother Res. 2006 Feb;20(2):96–102.
46. Koetter U, Schrader E, Käufeler R, Brattström A. A randomized, double blind, placebo-controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. Phytother Res. 2007 Sep;21(9):847–51.
47. Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther. 2001 Oct;26(5):363–7.
48. Lee J, Jung H-Y, Lee SI, Choi JH, Kim S-G. Effects of Passiflora incarnata Linnaeus on polysomnographic sleep parameters in subjects with insomnia disorder: a double-blind randomized placebo-controlled study. 2019;8.
49. Spinella M. The importance of pharmacological synergy in psychoactive herbal medicines. Altern Med Rev. 2002 Apr;7(2):130–7.
50. Abbasi B, Kimiagar M, Sadeghniiat K, Shirazi MM, Hedayati M, Rashidkhani B. The effect of magnesium supplementation on primary insomnia in elderly: A double-blind placebo-controlled clinical trial. J Res Med Sci. 2012 Dec;17(12):1161–9.
